NCT03825796View on ClinicalTrials.gov

CPX-351 Plus Enasidenib for Relapsed AML

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Recurrent Acute Myeloid Leukemia
Interventions
DRUG

Enasidenib Mesylate

Given PO

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (3)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92103

University of California San Diego, San Diego

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER